Palisade Bio
PALI
96 hedge funds and large institutions have $262M invested in Palisade Bio in 2026 Q1 according to their latest regulatory filings, with 31 funds opening new positions, 30 increasing their positions, 25 reducing their positions, and 20 closing their positions.
55% more first-time investments, than exits
New positions opened: 31 | Existing positions closed: 20
20% more repeat investments, than reductions
Existing positions increased: 30 | Existing positions reduced: 25
12% more funds holding
Funds holding: 86 → 96 (+10)
1.07% less ownership
Funds ownership: 91.19% → 90.12% (-1.1%)
18% less capital invested
Capital invested by funds: $319M → $262M (-$57.6M)
50% less funds holding in top 10
Funds holding in top 10: 2 → 1 (-1)
Top Buyers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
BGI
B Group Inc
Dallas,
Texas
|
+$12.6M |
| 2 |
Goldman Sachs
New York
|
+$8.76M |
| 3 |
Ameriprise
Minneapolis,
Minnesota
|
+$8.36M |
| 4 |
GPP
Great Point Partners
Greenwich,
Connecticut
|
+$6.19M |
| 5 |
Federated Hermes
Pittsburgh,
Pennsylvania
|
+$5.7M |
Top Sellers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
Point72 Asset Management
Stamford,
Connecticut
|
-$18.3M |
| 2 |
SC
Stempoint Capital
New York
|
-$9.85M |
| 3 |
CC
Commodore Capital
New York
|
-$7.75M |
| 4 |
PA
Perceptive Advisors
New York
|
-$5.68M |
| 5 |
VC
Vivo Capital
Palo Alto,
California
|
-$5.39M |
PALI Hedge Fund Activity: Q1 2026 in Review
96 of the 8,126 institutional investors tracked by Wall St. Rank reported a position in Palisade Bio (PALI) for Q1 2026, worth a combined $262M — down 18% from $319M a quarter earlier.
Buyers outnumbered sellers: 31 funds opened new PALI positions and 20 closed out — a net gain of 11 holders — while 30 added to existing stakes and 25 trimmed.
The largest buyer was B Group Inc, adding an estimated $12.6M. The largest seller was Point72 Asset Management, cutting an estimated $18.3M.
- 96 institutional investors held Palisade Bio (PALI) as of Q1 2026, up from 86 in Q4 2025.
- Funds reported $262M of Palisade Bio stock for Q1 2026, down 18% quarter-over-quarter.
- 31 funds opened new Palisade Bio positions in Q1 2026 and 20 closed out, a net change of +11 holders.
- The largest Palisade Bio buyer in Q1 2026 was B Group Inc, an estimated $12.6M added.
- The largest Palisade Bio seller in Q1 2026 was Point72 Asset Management, an estimated $18.3M sold.
Based on aggregated 13F filings for Q1 2026.